1. Home
  2. Companies
  3. PYC
  4. Material Events

PYC Therapeutics (ASX:PYC) — Material Events

ASX:PYC · 26 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 22 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
22
PYC Therapeutics Secures $537M in Placement, Eyes $600M Total Raise to Fuel RNA Drug PipelineHigh
PYC Therapeutics closes $537M placement, targets $600M total capital raise to fund RNA drug programs
4 Feb 2026 ·Capital Raising ·85
PYC Therapeutics Unveils Early Clinical Promise for RNA Therapies in Childhood BlindnessMedium
PYC Therapeutics presents promising Phase 1/2 data for RNA therapies targeting childhood blinding eye diseases at ARVO 2026
4 May 2026 ·Clinical Trial Data Presentation ·85
PYC Therapeutics Advances PYC-002 for Phelan-McDermid Syndrome with Promising Pre-Clinical DataMedium
PYC Therapeutics advances PYC-002 for Phelan-McDermid Syndrome with positive pre-clinical results, aiming for 2026 human trials
13 Oct 2025 ·Pre-Clinical Data Announcement ·85
PYC Therapeutics Advances PYC-001 with Promising Phase 1 Data in Blinding Eye DiseaseMedium
PYC Therapeutics reports positive Phase 1 data for PYC-001 in blinding eye disease ADOA, advancing to Phase 1/2 MAD study
5 Sept 2025 ·Clinical Trial Update ·85
PYC Therapeutics Advances RNA Pipeline with $600m Capital Boost and Clinical MilestonesMedium
PYC Therapeutics advances clinical pipeline and raises $600m capital in Q1 2026 update
28 Apr 2026 ·Quarterly Activity and Cash Flow Report ·85
PYC Therapeutics’ VP-001 Delivers Lasting Vision Gains in RP11 PatientsMedium
PYC Therapeutics' VP-001 shows sustained vision improvement in RP11 patients; FDA trial alignment planned for 2026
14 Nov 2025 ·Clinical Trial Update ·85
PYC Therapeutics Secures EMA Orphan Drug Status for RP11 Treatment CandidateMedium
PYC Therapeutics' RP11 Drug Candidate Receives EMA Orphan Drug Designation
27 Apr 2026 ·Regulatory Update ·85
PYC Therapeutics Advances RNA Pipeline Amid $22.8M Loss and $653M Capital RaiseHigh
PYC Therapeutics reports $22.8M half-year loss, advances RNA drug pipeline, announces $653M capital raise
23 Feb 2026 ·Appendix 4D and Interim Financial Statements ·85
PYC Therapeutics Raises $653M to Propel Four Genetic Disease Drug TrialsHigh
PYC Therapeutics launches AUD 653M equity raise to advance four genetic disease drug candidates through clinical trials
2 Feb 2026 ·Capital Raising ·85
PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOAMedium
PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOA
15 Apr 2026 ·Clinical Trial Progress Update ·80
PYC Therapeutics Advances Four RNA Drug Programs with $153m Cash BufferMedium
PYC Therapeutics advances four RNA drug programs with strong clinical progress and $153m cash runway
21 July 2025 ·Quarterly Activity and Cash Flow Report ·80
PYC Therapeutics Confirms Safety Milestone for PKD Drug Candidate PYC-003Medium
PYC Therapeutics reports safe dosing in Phase 1a/1b trial of PKD drug candidate PYC-003
19 Dec 2025 ·Clinical Trial Update ·80
PYC Therapeutics Advances PYC-001 After Safety Review Clears Phase 1 TrialMedium
PYC Therapeutics clears safety review for PYC-001 in ADOA, advancing to Phase 1/2 trial
9 Oct 2025 ·Clinical Trial Update ·80
PYC Therapeutics Launches Global Repeat Dose Trial for Vision-Restoring DrugMedium
PYC Therapeutics launches global Phase 1b repeat dose trial of PYC-001 for ADOA
21 Oct 2025 ·Clinical Trial Initiation Announcement ·80
PYC Therapeutics Advances PKD Drug with Phase 1b Multiple Dose TrialMedium
PYC Therapeutics Starts Phase 1b Trial for PKD Drug Candidate PYC-003
7 May 2026 ·Clinical Trial Initiation ·80
PYC Therapeutics Advances PYC-003 Trial with Final Dose Escalation and Patient DosingMedium
PYC Therapeutics advances PYC-003 clinical trial with dosing escalation and PKD patient dosing commencement
8 Aug 2025 ·Clinical Trial Update ·80
PYC Therapeutics Unveils Strong Safety Profile for PKD Drug Candidate PYC-003Medium
PYC Therapeutics Reports Favorable Safety Data for PKD Drug Candidate PYC-003 in Phase 1a Trial
29 Aug 2025 ·Clinical Trial Update ·80
PYC Therapeutics Advances RNA Drug Pipeline with Key Clinical Milestones and Robust Cash PositionMedium
PYC Therapeutics advances clinical pipeline with key milestones and strong cash position in Q3 2025 update
27 Oct 2025 ·Quarterly Activity Report and Appendix 4C ·80
PYC Therapeutics Advances RNA Drug Pipeline with $121M Cash BackingMedium
PYC Therapeutics advances four RNA drug candidates with strong clinical progress and $121M cash at end-2025
23 Jan 2026 ·Quarterly Activity Report and Appendix 4C ·80
PYC Therapeutics Raises $47M in Retail Entitlement Offer, Shares to Trade Next WeekMedium
PYC Therapeutics completes $47 million retail entitlement offer, new shares to trade from 9 March
4 Mar 2026 ·Capital Raising ·75
PYC Therapeutics Revamps Leadership Ahead of Critical 2027 MilestonesMedium
PYC Therapeutics appoints new Managing Director and Non-Executive Director amid strategic growth plans
22 Sept 2025 ·Board and Management Changes ·75
PYC Therapeutics Advances PKD Trial with Safety-Backed Dose EscalationMedium
PYC Therapeutics Advances PKD Drug Trial with Dose Escalation Approval
24 Nov 2025 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.